These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

802 related articles for article (PubMed ID: 19356598)

  • 1. Molecular hydrogen is protective against 6-hydroxydopamine-induced nigrostriatal degeneration in a rat model of Parkinson's disease.
    Fu Y; Ito M; Fujita Y; Ito M; Ichihara M; Masuda A; Suzuki Y; Maesawa S; Kajita Y; Hirayama M; Ohsawa I; Ohta S; Ohno K
    Neurosci Lett; 2009 Apr; 453(2):81-5. PubMed ID: 19356598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
    J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of acupuncture on 6-hydroxydopamine-induced nigrostratal dopaminergic neuronal cell death in rats.
    Kim YK; Lim HH; Song YK; Lee HH; Lim S; Han SM; Kim CJ
    Neurosci Lett; 2005 Aug 12-19; 384(1-2):133-8. PubMed ID: 15893426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treadmill exercise suppresses nigrostriatal dopaminergic neuronal loss in 6-hydroxydopamine-induced Parkinson's rats.
    Yoon MC; Shin MS; Kim TS; Kim BK; Ko IG; Sung YH; Kim SE; Lee HH; Kim YP; Kim CJ
    Neurosci Lett; 2007 Aug; 423(1):12-7. PubMed ID: 17644250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dietary restriction does not prevent nigrostriatal degeneration in the 6-hydroxydopamine model of Parkinson's disease.
    Armentero MT; Levandis G; Bramanti P; Nappi G; Blandini F
    Exp Neurol; 2008 Aug; 212(2):548-51. PubMed ID: 18508049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
    Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
    Fleming SM; Delville Y; Schallert T
    Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurotrophic effects of bone morphogenetic protein-7 in a rat model of Parkinson's disease.
    Harvey BK; Mark A; Chou J; Chen GJ; Hoffer BJ; Wang Y
    Brain Res; 2004 Oct; 1022(1-2):88-95. PubMed ID: 15353217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unilateral axonal or terminal injection of 6-hydroxydopamine causes rapid-onset nigrostriatal degeneration and contralateral motor impairments in the rat.
    Grealish S; Xie L; Kelly M; Dowd E
    Brain Res Bull; 2008 Nov; 77(5):312-9. PubMed ID: 18817852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical and immunocytochemical changes induced by intrastriatal 6-hydroxydopamine injection in the rat nigrostriatal dopamine neuron system: evidence for cell death in the substantia nigra.
    Ichitani Y; Okamura H; Nakahara D; Nagatsu I; Ibata Y
    Exp Neurol; 1994 Dec; 130(2):269-78. PubMed ID: 7867756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time-dependent alterations of peripheral immune parameters after nigrostriatal dopamine depletion in a rat model of Parkinson's disease.
    Engler H; Doenlen R; Riether C; Engler A; Niemi MB; Besedovsky HO; del Rey A; Pacheco-López G; Feldon J; Schedlowski M
    Brain Behav Immun; 2009 May; 23(4):518-26. PubMed ID: 19486644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
    Aponso PM; Faull RL; Connor B
    Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of repetitive transcranial magnetic stimulation on a model rat of Parkinson's disease.
    Yang X; Song L; Liu Z
    Neuroreport; 2010 Mar; 21(4):268-72. PubMed ID: 20087233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease.
    Reglodi D; Lubics A; Tamás A; Szalontay L; Lengvári I
    Behav Brain Res; 2004 May; 151(1-2):303-12. PubMed ID: 15084446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
    Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
    Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat.
    Walsh S; Finn DP; Dowd E
    Neuroscience; 2011 Feb; 175():251-61. PubMed ID: 21145947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum.
    Sanchez B; Relova JL; Gallego R; Ben-Batalla I; Perez-Fernandez R
    J Neurosci Res; 2009 Feb; 87(3):723-32. PubMed ID: 18816795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons.
    Rey P; Lopez-Real A; Sanchez-Iglesias S; Muñoz A; Soto-Otero R; Labandeira-Garcia JL
    Neurobiol Aging; 2007 Apr; 28(4):555-67. PubMed ID: 16621167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
    Saravanan KS; Sindhu KM; Senthilkumar KS; Mohanakumar KP
    Neurochem Int; 2006 Jul; 49(1):28-40. PubMed ID: 16490285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neural stem cell transplantation and melatonin treatment in a 6-hydroxydopamine model of Parkinson's disease.
    Sharma R; McMillan CR; Niles LP
    J Pineal Res; 2007 Oct; 43(3):245-54. PubMed ID: 17803521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.